Loading
Latest filing published 10 Aug 2026 for Aptevo Therapeutics Inc.. Read the official filing
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
No signal scores available.
This profile gathers the share dealings of Daniel Abdun-Nabi in Aptevo Therapeutics Inc., where the filings describe the role as board member. Over a trading history stretching from 1 June 2022 to 6 August 2026, the count stands at 6 filings.
None of the filings is a plain purchase or sale on the open market; they cover grants, option exercises and other movements. Such operations are usually part of compensation schedules, which makes them a weaker signal than an open-market trade.
The latest filing, published on 10 August 2026, reports an option exercise in Aptevo Therapeutics Inc. The median gap between a trade and its publication by SEC (Form 4) is 2 days. The legal deadline for a Form 4 is two business days after the transaction. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
6 of 6 declarations